Choose GHRP-2 if: You want GH stimulation without intense hunger GHRP-2's milder appetite effect makes it more practical for those who don't want to deal with powerful hunger surges You're combining with a GHRH analog Both peptides synergize equally well with CJC-1295 or Sermorelin, but GHRP-2's lower appetite impact makes the combination more comfortable You're lean and trying to stay lean Intense hunger can sabotage body composition goals You want the most studied diagnostic variant GHRP-2 has more clinical validation as a pituitary function test Choose GHRP-6 if: Appetite stimulation is a feature, not a bug Recovery from illness, post-surgery, cachexia, or deliberate caloric surplus goals benefit from GHRP-6's orexigenic effect You're interested in cytoprotective applications GHRP-6 has a more extensive literature on cardioprotection, neuroprotection, and tissue protection (GHRP-6 cardioprotection, 2024) You're underweight or struggling to eat enough The appetite boost can be therapeutic You want the historical "first" GHRP GHRP-6 has the longest research track record in the family Choose Neither (Consider Alternatives) if: You want minimal side effects Ipamorelin (most selective GHSR-1a agonist) You want maximum GH potency Hexarelin (strongest GHRP, but highest cortisol/prolactin)
As we stated in the CY 2026 OPPS/ASC proposed rule, we believe that race-conscious elements of diversity, equity and inclusion policies such as those historically required by the ACGME are generally impermissible under Federal law, as strongly suggested by the Supreme Court's ruling in Students for Fair Admissions v
M.LiuS.MaJ.WuG
Likewise, in a large retrospective cohort study of adults with T2DM, treatment with GLP-1RAs (N = 4,460) was associated with a 29% reduction in the risk of non-fatal ischemic stroke when compared to treatment with dipeptidyl peptidase-4 inhibitors (DPP-4i) (N = 13,380) [4]
